Array Rises On Binimetinib Data, 2016 Regulatory Submissions

Dec 17 2015

• By Mandy Jackson

Listen to this article

Array Biopharma gained 20.6% to close at $4.62 per share on Dec. 16 after the company said it will seek regulatory approvals for binimetinib based on results from the Phase III NEMO clinical trials, which showed the MEK inhibitor nearly doubled median progression-free survival (PFS) for NRAS-mutant melanoma patients to 2.8 months versus 1.5 months for dacarbazine (p

Array Biopharma gained 20.6% to close at $4.62 per share on Dec. 16 after the company said it will seek regulatory approvals for binimetinib based on results from the Phase III NEMO clinical trials, which showed the MEK inhibitor nearly doubled median progression-free survival (PFS) for NRAS-mutant melanoma patients to 2.8 months versus 1.5 months for dacarbazine (p<>

Binimetinib was a casualty of the massive asset swap between Novartis AG and GlaxoSmithKline PLC, in which Novartis acquired GSK's...

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Dec 05 2025
• By Xu Hu
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer
Sep 24 2025
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.